Spots Global Cancer Trial Database for metastatic pancreatic adenocarcinoma
Every month we try and update this database with for metastatic pancreatic adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | NCT02048384 | Metastatic Panc... | metformin alone... metformin (Arm ... rapamycin (Arm ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | NCT01233375 | Metastatic Panc... | CO-1.01 | 18 Years - | Clovis Oncology, Inc. | |
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | NCT02757391 | Colorectal Aden... Metastatic Chol... Metastatic Colo... Metastatic Dige... Metastatic Esop... Metastatic Gast... Metastatic Panc... Stage IV Colore... Stage IV Esopha... Stage IV Gastri... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Adoptive Immuno... Aldesleukin Cyclophosphamid... Laboratory Biom... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | NCT04229004 | Metastatic Panc... Metastatic Panc... | Gemcitabine com... Dose -mFOLFIRIN... Dose - Pamrevlu... Dose- Canakinum... Drug: Dose -SM-... | 18 Years - | Pancreatic Cancer Action Network | |
| A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas | NCT05383352 | Metastatic Panc... | Irinotecan lipo... Irinotecan lipo... Irinotecan lipo... Irinotecan lipo... Folinic Acid 5-Fluorouracil | 18 Years - | Ipsen | |
| LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | NCT02985125 | Metastatic Panc... | LEE011 Everolimus | 18 Years - | Georgetown University | |
| Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | NCT02227940 | Advanced Malign... ALK Positive Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Ceritinib Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Albu... Pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | NCT04548752 | Metastatic Panc... Pancreatic Aden... Stage IV Pancre... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Pembrolizumab | 18 Years - | National Cancer Institute (NCI) | |
| Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | NCT04132505 | Metastatic Panc... Stage IV Pancre... | Binimetinib Hydroxychloroqu... | 18 Years - | M.D. Anderson Cancer Center | |
| p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | NCT02847000 | Metastatic Panc... | Tetrahydrouridi... Decitabine | 18 Years - | Case Comprehensive Cancer Center | |
| The Study of Metastatic Pancreatic Adenocarcinoma | NCT01415713 | Metastatic Panc... | S-1,Leucovorin,... | 20 Years - 75 Years | National Health Research Institutes, Taiwan | |
| SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | NCT04050085 | Metastatic Panc... Refractory Panc... Stage IV Pancre... | Nivolumab Radiation Thera... TLR9 Agonist SD... | 18 Years - | University of California, Davis | |
| Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma | NCT05102721 | Metastatic Panc... | Avelumab and Pe... | 18 Years - | Vaccinex Inc. | |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | NCT02650635 | Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... | Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT... | 18 Years - | Mayo Clinic | |
| Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | NCT03095781 | Colorectal Aden... Metastatic Panc... Recurrent Color... Recurrent Pancr... Stage III Color... Stage III Pancr... Stage IIIA Colo... Stage IIIB Colo... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable Pa... | XL888 Pembrolizumab | 18 Years - | Emory University | |
| Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer | NCT06381154 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Biopsy Biospecimen Col... Computed Tomogr... Endoscopic Ultr... Fluorouracil Irinotecan Leucovorin Lymph Node Biop... Magnetic Resona... Oxaliplatin Pembrolizumab Photodynamic Th... Positron Emissi... Questionnaire A... Verteporfin | 18 Years - | Mayo Clinic | |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | NCT04233866 | Metastatic Panc... Stage IV Pancre... | Fluorouracil Gemcitabine Gemcitabine Hyd... Leucovorin Leucovorin Calc... Liposomal Irino... Nab-paclitaxel Quality-of-Life... Questionnaire A... | 70 Years - | Eastern Cooperative Oncology Group | |
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | NCT04652206 | Metastatic Panc... Locally Advance... Inoperable Dise... Localized Pancr... | SCO-101 Gemcitabine Nab paclitaxel | 18 Years - | Scandion Oncology A/S | |
| Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | NCT04058964 | Metastatic Panc... Stage IV Pancre... | Pegylated Recom... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | NCT04787991 | Metastatic Panc... | Nivolumab (Coho... Ipilimumab (Coh... Hydroxychloroqu... Nab-paclitaxel ... Gemcitabine (ge... NG350A (Cohort ... | 18 Years - | Cancer Insight, LLC | |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | NCT02045589 | Pancreatic Aden... Metastatic Panc... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | NCT01954992 | Metastatic Panc... | Glufosfamide Fluorouracil | 18 Years - | Eleison Pharmaceuticals LLC. | |
| Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma | NCT01204372 | Metastatic Panc... | Gemcitabine - T... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer | NCT02907099 | Metastatic Panc... Recurrent Pancr... Stage IV Pancre... | CXCR4 Antagonis... Pembrolizumab Pharmacological... | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma | NCT03974854 | Metastatic Panc... | XELOXIRI-3 Gemcitabine | 65 Years - | Centre Hospitalier Universitaire de Besancon | |
| A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | NCT00998322 | Metastatic Panc... | REOLYSIN Gemcitabine | 18 Years - | Oncolytics Biotech | |
| Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas | NCT05926206 | Metastatic Panc... | Devimistat Modified FOLFIR... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma | NCT03943667 | Metastatic Panc... | Gemcitabine Paclitaxel | 18 Years - | UNICANCER | |
| Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma | NCT03943667 | Metastatic Panc... | Gemcitabine Paclitaxel | 18 Years - | UNICANCER | |
| Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | NCT02333188 | Adenocarcinoma ... Adult Cholangio... Gallbladder Car... Gastric Adenoca... Malignant Gastr... Metastatic Panc... Pancreatic Aden... Stage III Ampul... Stage III Pancr... Stage IIIA Gall... Stage IIIA Gast... Stage IIIB Gall... Stage IIIB Gast... Stage IV Ampull... Stage IV Gallbl... Stage IV Gastri... Stage IV Pancre... | Paclitaxel Albu... Leucovorin Calc... Irinotecan Hydr... Fluorouracil Laboratory Biom... | 18 Years - | University of Chicago | |
| Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | NCT06043713 | Metastatic Colo... Metastatic Lung... Metastatic Panc... Stage IV Colore... Stage IV Lung C... Stage IV Pancre... | Bendamustine Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Echocardiograph... Fludarabine Leukapheresis Magnetic Resona... Multigated Acqu... Positron Emissi... T-cell Receptor... | 18 Years - | Fred Hutchinson Cancer Center | |
| Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | NCT02562898 | Metastatic Panc... | Ibrutinib Paclitaxel Gemcitabine | 18 Years - | University of California, San Francisco | |
| Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer | NCT01830322 | Metastatic Panc... | CPI-613 Gemcitabine Any non-gemcita... | 18 Years - 85 Years | Cornerstone Pharmaceuticals | |
| Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer | NCT01360853 | Metastatic Panc... | ON 01910.Na Gemcitabine Gemcitabine | 18 Years - | Traws Pharma, Inc. | |
| Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer | NCT02671890 | Metastatic Panc... Refractory Mali... Stage IV Pancre... | Chemotherapy Disulfiram Gemcitabine Hyd... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| BATs Treatment for Pancreatic Cancer, Phase Ib/II | NCT03269526 | Locally Advance... Metastatic Panc... | EGFR BATs after... | 18 Years - | University of Virginia | |
| Olaparib in Treating Patients With Stage IV Pancreatic Cancer | NCT02677038 | Metastatic Panc... Pancreatic Duct... Stage IV Pancre... | Olaparib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. | NCT01510561 | Metastatic Panc... Pancreatic Canc... Metastatic Panc... | 90Y-hPAM4 90Y-hPAM4 90Y-hPAM4 + gem... | 18 Years - | Gilead Sciences | |
| Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | NCT05642962 | Metastatic Panc... Metastatic Panc... Metastatic Panc... Metastatic Panc... Pancreatic Carc... Pancreatic Carc... Pancreatic Carc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... PDAC PDAC - Pancreat... | Pertzye | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT01585805 | Locally Advance... Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Gemcitabine Gemcitabine Hyd... Magnetic Resona... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | NCT04616534 | Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa... | Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine | 18 Years - | National Cancer Institute (NCI) | |
| Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma | NCT03974854 | Metastatic Panc... | XELOXIRI-3 Gemcitabine | 65 Years - | Centre Hospitalier Universitaire de Besancon | |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | NCT03257761 | Extrahepatic Bi... Gallbladder Ade... Metastatic Panc... Recurrent Chola... Recurrent Gallb... Recurrent Hepat... Recurrent Intra... Recurrent Pancr... Stage III Gallb... Stage III Hepat... Stage III Intra... Stage III Pancr... Stage IIIA Gall... Stage IIIA Hepa... Stage IIIB Gall... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Gallbl... Stage IV Hepato... Stage IV Pancre... Stage IVA Gallb... Stage IVA Hepat... Stage IVA Intra... Stage IVB Gallb... Stage IVB Hepat... Stage IVB Intra... Unresectable Ga... Unresectable Pa... | Durvalumab Guadecitabine | 18 Years - | University of Southern California | |
| A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. | NCT01510561 | Metastatic Panc... Pancreatic Canc... Metastatic Panc... | 90Y-hPAM4 90Y-hPAM4 90Y-hPAM4 + gem... | 18 Years - | Gilead Sciences | |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | NCT02194829 | Metastatic Panc... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | AZD1775 Gemcitabine Nab-paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | NCT02650635 | Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... | Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT... | 18 Years - | Mayo Clinic | |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | NCT04191421 | Metastatic Panc... Stage IV Pancre... | Siltuximab Spartalizumab | 18 Years - | Emory University | |
| Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | NCT01729481 | Metastatic Panc... | Gemcitabine Erlotinib Oxaliplatin Folinic Acid Irinotecan 5-FU | 18 Years - 75 Years | Ludwig-Maximilians - University of Munich | |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | NCT02498613 | Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr... | 18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer | NCT02671890 | Metastatic Panc... Refractory Mali... Stage IV Pancre... | Chemotherapy Disulfiram Gemcitabine Hyd... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | NCT04616534 | Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa... | Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine | 18 Years - | National Cancer Institute (NCI) | |
| Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma | NCT01204372 | Metastatic Panc... | Gemcitabine - T... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT01585805 | Locally Advance... Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Gemcitabine Gemcitabine Hyd... Magnetic Resona... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | NCT04132505 | Metastatic Panc... Stage IV Pancre... | Binimetinib Hydroxychloroqu... | 18 Years - | M.D. Anderson Cancer Center | |
| Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer | NCT06018883 | Metastatic Panc... | Ascorbate Nab paclitaxel Gemcitabine | 18 Years - 80 Years | Fudan University | |
| A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | NCT04229004 | Metastatic Panc... Metastatic Panc... | Gemcitabine com... Dose -mFOLFIRIN... Dose - Pamrevlu... Dose- Canakinum... Drug: Dose -SM-... | 18 Years - | Pancreatic Cancer Action Network | |
| Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas | NCT05926206 | Metastatic Panc... | Devimistat Modified FOLFIR... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | NCT05249101 | Metastatic Panc... | Ivaltinostat Capecitabine | 18 Years - | CG Pharmaceuticals, Inc | |
| Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | NCT02324543 | Metastatic Panc... | Gemcitabine Taxotere Xeloda Cisplatin Irinotecan | 18 Years - 76 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | NCT05034627 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... | Biopsy Calaspargase Pe... Cobimetinib | 18 Years - | OHSU Knight Cancer Institute | |
| LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | NCT02985125 | Metastatic Panc... | LEE011 Everolimus | 18 Years - | Georgetown University | |
| A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | NCT00998322 | Metastatic Panc... | REOLYSIN Gemcitabine | 18 Years - | Oncolytics Biotech | |
| Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | NCT03095781 | Colorectal Aden... Metastatic Panc... Recurrent Color... Recurrent Pancr... Stage III Color... Stage III Pancr... Stage IIIA Colo... Stage IIIB Colo... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable Pa... | XL888 Pembrolizumab | 18 Years - | Emory University | |
| Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | NCT01760252 | Metastatic Panc... | Capecitabine, O... | 18 Years - | Beth Israel Medical Center | |
| A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | NCT04229004 | Metastatic Panc... Metastatic Panc... | Gemcitabine com... Dose -mFOLFIRIN... Dose - Pamrevlu... Dose- Canakinum... Drug: Dose -SM-... | 18 Years - | Pancreatic Cancer Action Network | |
| Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | NCT02575508 | Colon Adenocarc... Metastatic Panc... Pancreatic Aden... Pancreatic Duct... Rectal Adenocar... Stage III Pancr... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Pancre... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | Fluorouracil Irinotecan Hydr... Laboratory Biom... Oxaliplatin pan FGFR Kinase... Pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | NCT04616534 | Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa... | Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine | 18 Years - | National Cancer Institute (NCI) | |
| A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | NCT05484011 | Metastatic Panc... | odetiglucan CDX-1140 | 18 Years - | HiberCell, Inc. | |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | NCT04387071 | Locally Advance... Metastatic Panc... Stage IV Pancre... Unresectable Ma... | Agonistic Anti-... VLP-encapsulate... | 18 Years - | University of Southern California | |
| Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | NCT01954992 | Metastatic Panc... | Glufosfamide Fluorouracil | 18 Years - | Eleison Pharmaceuticals LLC. | |
| iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | NCT03608631 | KRAS NP_004976.... Metastatic Panc... Pancreatic Duct... Stage IV Pancre... | Mesenchymal Str... | 18 Years - | M.D. Anderson Cancer Center | |
| Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer | NCT04524702 | Advanced Pancre... Metastatic Panc... Stage IV Pancre... | Gemcitabine Hydroxychloroqu... Nab-paclitaxel Paricalcitol | 18 Years - | Emory University | |
| Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma | NCT01204372 | Metastatic Panc... | Gemcitabine - T... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | NCT02045589 | Pancreatic Aden... Metastatic Panc... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | NCT02498613 | Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr... | 18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer | NCT03006302 | Metastatic Panc... | Epacadostat Pembrolizumab CRS-207 CY GVAX | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | NCT05249101 | Metastatic Panc... | Ivaltinostat Capecitabine | 18 Years - | CG Pharmaceuticals, Inc | |
| Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer | NCT01830322 | Metastatic Panc... | CPI-613 Gemcitabine Any non-gemcita... | 18 Years - 85 Years | Cornerstone Pharmaceuticals | |
| Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. | NCT04348045 | Metastatic Panc... | Arm A - Olapari... ARM B - durvalu... ARM C FOLFIRI | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | NCT04387071 | Locally Advance... Metastatic Panc... Stage IV Pancre... Unresectable Ma... | Agonistic Anti-... VLP-encapsulate... | 18 Years - | University of Southern California |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
